CMS Will Cover Warfarin Gene Tests In Clinical Trials, But That's It
This article was originally published in The Gray Sheet
Executive Summary
Medicare will only cover genetic testing for individual response to the blood-thinner warfarin in the context of controlled clinical studies, effective immediately, CMS said Aug. 3
You may also be interested in...
Studies Find Limited Support For Genotyping-Guided Warfarin Dosing
The overall message of three trials published recently in The New England Journal of Medicine: “This pharmacogenetic testing has either no usefulness in the initial dosing of vitamin K antagonists or, at best, marginal usefulness, given the cost and effort required to perform this testing,” according to an editorial also in NEJM.
CMS Will Weigh Three New Tech Assessments On Genetic Testing For Cancer
Two of the assessments are intended to inform an upcoming Medicare Evidence Development and Coverage Advisory Committee meeting.
CMS Will Weigh Three New Tech Assessments On Genetic Testing For Cancer
Two of the assessments are intended to inform an upcoming Medicare Evidence Development and Coverage Advisory Committee meeting.